AbbVie inks deal with Parvus; Sofinnova invests in Cure51

Plus, news about Aquestive Therapeutics and Cybin:

AbbVie enlists Parvus Therapeutics for IBD pact: AbbVie will have the option to develop and commercialize Parvus’ therapies for inflammatory bowel diseases (IBD). Parvus’ therapies trigger T cells to grow and turn into regulatory T cells — a specialized type of T cell that can suppress the immune system.

The deal adds another pipeline option to AbbVie’s IBD franchise, which includes Rinvoq and Skyrizi. And it adds to Parvus’ list of pharma collaborators, which include Novartis and Roche’s Genentech. Financial details of the licensing deal were not disclosed, though Parvus could receive a potential equity investment from AbbVie. — Lei Lei Wu

Sofinnova’s latest seed investment: Cure51, a Paris-based startup, raised €15 million in a seed round led by Sofinnova Partners and included Hitachi Ventures, Life Extension Ventures, Xavier Niel, and Datadog CEO and co-founder…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks